Summer Street Upgrades United Therapeutics (UTHR) to Buy; Evidence of Continued Strong Tyvaso Rollout
Tweet Send to a Friend
Summer Street upgrades United Therapeutics (Nasdaq: UTHR) from Neutral to Buy. Price target $68.
Summer analyst says, "We completed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Summer analyst says, "We completed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
